Indraprastha Medical Corporation Ltd.
Snapshot View

82.45 -1.40 ▼-1.7%

23 July 2021, 04:00:00 P.M.
Volume: 62,383

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.apollohospdelhi.com
Financial Indicators
Market Cap 755.84 Cr.
Earnings per share (EPS) 0.25 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 324.54 Trailing Twelve Months Ending 2021-03
Industry PE 223.80 Trailing Twelve Months Ending 2021-03
Book Value / Share 29.75 Trailing Twelve Months Ending 2021-03
Price to Book Value 2.77 Calculated using Price: 82.45
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 9.17 Cr. 91,673,000 Shares
FaceValue 10
Company Profile

Indraprastha Medical Corporation (Indraprastha) was incorporated as public limited company on  March 16,1988 with the ROC and obtained the certificate of commencement of business on April 7,1988.It is a Delhi-based healthcare company which operates through Indraprastha Apollo Hospital. Indraprastha Apollo, a 695 bed specialty hospital, was commissioned on December 1995 in collaboration with New Delhi administration. The hospital, spread across an area of 675,000 sq ft, is the largest corporate hospital in India and the fourth largest in the world. The hospital has various centres such as Apollo cardiac center, Apollo cancer center and Apollo surgical science center, among others. The company has operated on around 7.4 million patients. The group also owns 12 hospitals and four clinics. It is running a multi super-specialty hospital.

Business area of the company :

It offers a range of diagnostic, medical, and surgical facilities for the care of its patients. The company provides treatments in the areas of anaesthesiology, oncology, cardiology, neurology, orthopedics, nephrology, ophthalmology, nuclear medicine, pediatrics, physiotherapy and rehabilitation, psychiatry and psychology, radiology, urology and andrology, gastroenterology, gynecology and obstetrics, dermatology, dietetics and nutrition, and respiratory and sleep medicine. It also offers various surgical services, including dental, cardiothoracic, neuro, vascular, joint, plastic and cosmetic, and general surgeries. In addition, the company’s diagnostic services include lab services, radio-diagnosis, nuclear medicine, endoscopy lab, bronchoscopy lab, and blood bank. Further, it offers ambulance and air ambulance services, as well as out patient consultation services.

As of March 31, 2009, Indraprastha Apollo Hospitals performed around 2000 cardiac surgeries, 400 joint replacements, 1000 onco surgeries, 90 liver transplants and 135 renal transplants. The company's hospitals are located in Chennai, Hyderabad, Kolkata, Ahmedabad, Bangalore, Bilaspur and Madurai.

Milestones:

  • 1988- The company was incorporated as public limited company on 16th March with the ROC and obtained the certificate of commencement of business on 7th of April. The hospital has 4 cardio-thoracic surgery operation theatres (OTs), 2 neurosurgery OTs, 5 major OTs, 4 minor OTs, 2 emergency OTs and 1 maternity OT.  These OTs are being used for the various specialties/services that are available in the hospital. 
  • 1990 -The company entered into an agreement with Indian Hospital Corporation on 17th July. IHCL is providing technical consultancy and project consultancy for setting up, commissioning and functioning of the hospital. The Company has also installed 2 DG sets of 750 KVA capacity each as standby arrangements. Three steam boilers with a capacity of 2000 kg/hr each with requisite storage and distribution systems have been installed to meet the requirement of steam. 
  • 1992 -The company entered into an agreement with MCS for redressal of investor grievances for a period of six months from the last date of dispatch of letter of allotment advice/share certificates/refund orders. 
  • 1996 - The Cardiology and Cardiothoracic Surgery have state-of-the-art facilities for cardiac care and treatment.  3 Catheterization laboratories with Digital imaging & electrophysiology facilities have been set-up. The Neuro Sciences department is one of the few centres in Asia providing advanced neuro surgery facilities. Since August, 300 beds have been commissioned with an average occupancy of 200 beds. The Company is setting up Indraprastha Apollo Hospitals a 695 bed multi-disciplinary super specialty tertiary care hospital with state of the art facilities at a site on Delhi-Mathura Road, near Sarita Vihar, New Delhi. The Company proposes to set-up satellite centres in strategic locations in and around Delhi which will have 8-10 consultancy rooms and basic diagnostic facilities. An Incinerator with a capacity of 125 kgs per hour has been installed for disposal of combustible waste, infectious waste, human tissue, bandage, dressing linen etc. IMCL has installed compressors for compressed air and medical gases. The company has entered into an equipment lease agreement with IHCL for leasing of specified medical equipment.
  • 1997- Indraprastha Medical Corporation entered the capital market with a public issue of 2,29,18,900 equity shares of Rs.10 each for cash at par aggregating to Rs.22,91,83,000. Indraprastha Medical Corporation is a multi-speciality 600-bed corporate hospital being set up in New Delhi. Besides the hospital complex the corporate hospital also has plans to set up five satellite centres. The first joint sector venture in healthcare in the country was set up in collaboration with NCT (National Capital Territory) of Delhi, bringing together the strategic focus and operational advantages of the private sector. 
  • 1998 - Recently, a combined team of cardiologists and neurologists successfully developed a new technique of safely embolizing septal artery without affecting vital circulation of the rest of the heart muscle.  The hardware was a combination of material used in coronary angioplasty and cerebral AVM repairs.  This procedure has been performed for the first time in the world. A new technique thrombolysis devised by the neuroradiology unit to treat early stroke victims involves injection of a special medicine directly into the clot within an artery in the brain to dissolve it. Palliative Medicine, for the first time in the country, being offered as a dedicated speciality service by the hospital, is a concept of medical care that provides for people who are terminally ill. The Assisted Reproductive Unit comprising a team of highly skilled and experienced specialists trained in the UK and USA has been commissioned. Eight national and international conferences held with renowned faculty drawn from across ten countries, most important of them being OPTIMA 98 - a 3-day international conference conducted by the Department of Neurosciences, being the first of its kind in the country. A six-month certificate course on Operation Theatre Technology and Tertiary Nursing Care for qualified registered nurses graduated from various institutions commences 1 July, comprising two semesters each of clinical and theoretical practice. The hospital is one of the multicenteric multinational drug trial centres for drug control studies for hypertension. The hospital is now on the internet with the most comprehensive website with, inter alia, an animated walkthru of the hospital, facility for online appointments and updates on all available services. 
  • 1999- The group also has an ambitious plan of setting up hospitals in Ludhiana, Lucknow, Ahmedabad, Vizag and possibly Calcutta and Mumbai. Abroad, after Dubai and Muscat, the company is looking at East Africa and Sri Lanka and Bangladesh. The Apollo Hospitals group has no immediate plans to include its Delhi-based associate company -- Indraprastha Medical Corporation (IMCL) -- in the on-going consolidation process involving merger of the remanning three group companies into single entity. Besides the Delhi Government, IMCL has been promoted by Dr. Reddy and Shrodders Ventures of the UK who together hold 49 per cent stake in the company.  The public holds a 25 per cent stake in IMCL. The agreement entered into between the promoters in 1998 gives an option to the Delhi Government to divest its 26 per cent stake in IMCL in three tranches once the Indraprastha Apollo Hospital becomes fully operational.  The stake has to be divested at a pre-determined compounded rate or the prevailing market price, whichever is higher. 2005 Delist from The Delhi Stock Exchange Association Limited w.e.f. January 20, 2005.

Future Plans

Indraprastha Medical Corporation plans to set up more than ten satellite clinics in and around Delhi to facilitate easy availability of Apollo-type medical services to a larger cross-section of society. These clinics are to take the shape of mini-hospitals with all basic back-up emergency services mainly aimed at providing post-treatment facilities to Apollo Hospitals patients. Each clinic would cost between Rs 10 to Rs 15 million. It also plans to acquire some of the existing small clinics situated at various locations, upgrade them and start as Apollo clinics.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-1.67%
1 Week
-2.37%
1 Month
-4.18%
3 Month
+41.79%
6 Month
+46.84%
1 Year
+61.67%
2 Year
+129.67%
5 Year
+50.32%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 17.50 17.42 19.79 17.02 11.68 11.55 9.11 11.93 17.05
Return on Capital Employed (%) 20.34 22.98 25.78 23.29 17.72 16.98 14.40 18.29 20.15
Return on Assets (%) 7.10 6.85 7.99 7.30 5.42 5.71 4.74 6.65 10.01

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 159 171 187 195 224 231 232 244 268
Non Curr. Liab. 66 71 70 53 46 42 62 54 42
Curr. Liab. 176 196 192 194 191 186 138 124 140
Minority Int.
Equity & Liab. 402 438 449 442 461 458 432 422 449
Non Curr. Assets 283 306 302 293 308 301 299 287 308
Curr. Assets 119 132 147 149 152 158 133 136 141
Misc. Exp. not W/O
Total Assets 402 438 449 442 461 458 432 422 449

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 522 607 678 714 755 766 753 788 831
Other Income 1 1 1 1 2 0 1 0 1
Total Income 523 608 679 715 758 766 753 789 831
Total Expenditure -455 -528 -587 -630 -676 -687 -680 -707 -744
PBIDT 68 80 92 86 82 79 74 81 87
Interest -6 -9 -10 -8 -7 -8 -9 -7 -6
Depreciation -22 -26 -28 -28 -35 -31 -31 -30 -33
Taxation -13 -17 -19 -17 -14 -15 -13 -16 -5
Exceptional Items
PAT 27 29 35 32 24 26 21 28 44

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 55 67 58 64 62 28 48 75 86
Cash Fr. Inv. -28 -54 -22 -29 -33 -22 -30 -17 -40
Cash Fr. Finan. -27 -13 -36 -35 -30 -5 -17 -44 -43
Net Change 1 0 0 0 0 0 1 14 4
Cash & Cash Eqvt 1 2 2 2 2 2 3 17 20

Shareholding Pattern View Details

9 Qtrs 2019-03 (%) 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%)
Promoter 51.00 51.00 51.00 51.00 51.00 51.00 51.00 51.00 51.00
Public 49.00 49.00 49.00 49.00 49.00 49.00 49.00 49.00 49.00
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Sat, 24 Jul 2021
Postal Ballot - Voting Results And Report Of Scrutinizer
We wish to inform you that the Company has conducted the process of Postal Ballot for seeking approval of its shareholders by way of Postal Ballot voting (only through e-voting) for the businesses as set out in the Postal Ballot notice dated 9th June 2021. The voting ended on 23rd July 2021.
In this regard enclosed please find the following-

(1) Voting results as required under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations - Annexure - I; and
(2) Report of Scrutinizer dated 24th July 2021 pursuant to Section 108 of the Companies Act 2013 read with the Companies (Management and Administration) Rules 2014 - Annexure- II.
This is for your information and records.
Tue, 20 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
In compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 enclosed please find herewith a Certificate dated 5th July 2021 issued by M/s. Link Intime India Private Limited Registrar & Share Transfer Agent of the Company for the quarter ended 30th June 2021.

This is for your information and record.
Sat, 17 Jul 2021
Shareholding for the Period Ended June 30 2021
Indraprastha Medical Corporation Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here

Technical Scans View Details

Fri, 23 Jul 2021
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
Closing Near 50 EMA Closing Near 50 EMA
Close Crossing 50 EMA From Above Close Crossing 50 EMA From Above
ADX Crossing 25 From Above ADX Crossing 25 From Above
+DI Crossing -DI From Above +DI Crossing -DI From Above

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%